loading

Dechra Pharmaceuticals PLC

Overview

Welcome to Dechra Pharmaceuticals PLC
Growing Our Geographical Footprint
Dechra's Strengths
Highlights
Chairman's View

Strategic Report

Our Marketplace
Global Market Dynamics
Product Market Dynamics
Our Business Model
Creating Value for Our Stakeholders
Delivering Our Strategy
Overview
Strategic Timeline
Our Achievements and Progress
Chief Executive Officer's Statement
Q&A with Ian Page
Financial Review
Key Performance Indicators
Strategy in Action
Pipeline Delivery
Portfolio Focus
Geographical Expansion
Product Development
Product Development Process
Product Development Pipeline
International Product Offering
Corporate Social Responsibility
Overview
Our People
Our Community
Our Environment
Our Business
How the Business Manages Risk
Overview
Understanding Our Key Risks

Governance

Letter from the Chairman on Governance
Compliance with the Code
Corporate Governance
Board
Senior Executive Team
Leadership
Effectiveness
Accountability
Relations with Shareholders
Audit Committee Report
Letter from the Audit Committee Chairman
Audit Committee Report
Nomination Committee Report
Letter from the Nomination Committee Chairman
Nomination Committee Report
Director's Remuneration Report
Letter from the Remuneration Committee Chairman
Remuneration at a Glance
2019 Annual Report on Remuneration
Directors' Remuneration Policy
Directors' Report - Other Disclosures
Statement of Directors' Responsibilities

Financial Statements

Independent Auditors' Report to the Members of Dechra Pharmaceuticals PLC
Consolidated Income Statement
Consolidated Statement of Comprehensive Income
Consolidated Statement of Financial Position
Consolidated Statement of Changes in Shareholders' Equity
Consolidated Statement of Cash Flows
Notes to the Consolidated Financial Statements
Company Statement of Financial Position
Company Statement of Changes in Shareholders' Equity
Notes to the Company Financial Statements
Financial History

Company Information

Glossary
Shareholder Information
Advisers

Annual Report and Accounts for the year ended 30 June 2019

Financials

20. Current Tax Liabilities

  • Home
  • Financial Statements
  • Notes to the Consolidated Financial Statements
  • 20. Current Tax Liabilities
2019
£m		2018
£m
Corporation tax receivable7.9–
Corporation tax payable(16.3)(5.9)
(8.4)(5.9)
  • previous 19. Trade and Other Payables
  • next 21. Borrowings
  • Overview
  • Strategic Report
  • Governance
  • Financial Statements
  • Company Information

©2019 Dechra Pharmaceuticals PLC

www.dechra.com
  • Site Map
  • Accessibility
  • Cookies

Designed and developed by jonesandpalmer.co.uk